Editas Medicine (EDIT) Competitors $3.46 +0.10 (+2.98%) Closing price 04:00 PM EasternExtended Trading$3.43 -0.03 (-0.87%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. BEAM, CRSP, NTLA, ZYME, MENS, NAGE, BGM, GHRS, XERS, and SIONShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Zymeworks (ZYME), Jyong Biotech (MENS), Niagen Bioscience (NAGE), BGM Group (BGM), GH Research (GHRS), Xeris Biopharma (XERS), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Intellia Therapeutics Zymeworks Jyong Biotech Niagen Bioscience BGM Group GH Research Xeris Biopharma Sionna Therapeutics Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Is BEAM or EDIT more profitable? Beam Therapeutics has a net margin of -609.24% compared to Editas Medicine's net margin of -701.06%. Beam Therapeutics' return on equity of -44.24% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-609.24% -44.24% -30.97% Editas Medicine -701.06%-139.24%-63.87% Does the media favor BEAM or EDIT? In the previous week, Beam Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.40 beat Beam Therapeutics' score of -0.10 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, BEAM or EDIT? Editas Medicine has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M35.10-$376.74M-$4.61-4.81Editas Medicine$32.31M8.96-$237.09M-$3.04-1.14 Do insiders and institutionals have more ownership in BEAM or EDIT? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by insiders. Comparatively, 1.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, BEAM or EDIT? Beam Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Do analysts recommend BEAM or EDIT? Beam Therapeutics currently has a consensus target price of $48.75, suggesting a potential upside of 119.89%. Editas Medicine has a consensus target price of $4.70, suggesting a potential upside of 35.84%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Beam Therapeutics is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.31 SummaryBeam Therapeutics beats Editas Medicine on 12 of the 17 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.64M$3.04B$5.67B$9.46BDividend YieldN/A2.49%4.01%4.00%P/E Ratio-1.1421.3928.0920.14Price / Sales8.96265.12416.0798.39Price / CashN/A41.6635.9658.29Price / Book2.128.208.565.81Net Income-$237.09M-$55.10M$3.24B$258.35M7 Day Performance21.83%7.71%4.59%3.95%1 Month Performance64.76%21.81%12.90%14.86%1 Year Performance-38.32%6.52%35.37%19.27% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.0697 of 5 stars$3.46+3.0%$4.70+35.8%-35.5%$289.64M$32.31M-1.14230Gap UpBEAMBeam Therapeutics2.0719 of 5 stars$19.58-7.5%$48.75+149.0%-20.4%$1.97B$63.52M-4.25510Analyst UpgradeAnalyst RevisionCRSPCRISPR Therapeutics1.7562 of 5 stars$52.73-6.5%$71.75+36.1%+17.2%$4.55B$37.31M-11.67460Trending NewsAnalyst ForecastAnalyst RevisionGap UpNTLAIntellia Therapeutics4.5087 of 5 stars$11.48-3.9%$33.37+190.7%-46.7%$1.19B$57.88M-2.20600Analyst RevisionZYMEZymeworks3.028 of 5 stars$12.88-3.5%$21.00+63.0%+39.6%$897.52M$93.38M-8.59460Upcoming EarningsMENSJyong BiotechN/A$11.70+0.8%N/AN/A$889.55MN/A0.0031News CoverageQuiet Period ExpirationNAGENiagen Bioscience1.6564 of 5 stars$11.08-1.6%$13.22+19.3%N/A$872.77M$99.60M65.18120BGMBGM GroupN/A$8.90+10.1%N/AN/A$865.26M$25.10M0.00298News CoverageHigh Trading VolumeGHRSGH Research2.26 of 5 stars$15.99-3.0%$32.00+100.1%+39.7%$831.93MN/A-20.2410News CoverageXERSXeris Biopharma3.9497 of 5 stars$5.29-2.8%$6.25+18.1%+109.0%$827.25M$203.07M-17.63290News CoverageSIONSionna TherapeuticsN/A$18.53-7.1%$38.50+107.8%N/A$817.54MN/A0.0035 Related Companies and Tools Related Companies Beam Therapeutics Competitors CRISPR Therapeutics Competitors Intellia Therapeutics Competitors Zymeworks Competitors Jyong Biotech Competitors Niagen Bioscience Competitors BGM Group Competitors GH Research Competitors Xeris Biopharma Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts